Clinical Trials Directory

Trials / Completed

CompletedNCT02605681

Midkine and ACE-Ang II Induced Endothelial Injury in Sepsis

Plasma Midkine Associated Organ Dysfunction and Vascular Injury in Sepsis

Status
Completed
Phase
Study type
Observational
Enrollment
26 (actual)
Sponsor
Southeast University, China · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Accepted

Summary

Plasma midkine has reported to be elevated in infection and a regulator of angiotensin-converting enzyme (ACE). We aimed to investigate the plasma midkine in septic patients and its association with 28-day mortality and organ function, and also with plasma ACE and angiotensin II.

Detailed description

This study showed that Ang II induced endothelial injury in sepsis patients. Midkine has been shown to regulate the renin-angiotensin system and acts in the upstream signaling pathway of angiotensin (ANG) II. The investigators want to access the relationship between midkine level and ACE-Ang II induced endothelial injury in sepsis

Conditions

Timeline

Start date
2016-11-01
Primary completion
2018-03-31
Completion
2018-06-15
First posted
2015-11-16
Last updated
2018-12-12

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT02605681. Inclusion in this directory is not an endorsement.